| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 10/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/24/2023 |
4
| Rivard Paul (Chief Legal Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Bought 150,000 shares
@ $1.11, valued at
$166.5k
|
|
| 08/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/14/2023 |
8-K
| Other Events Interactive Data |
| 06/30/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 06/30/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/09/2023 |
4
| Chapman Christopher C JR (President, Chief Med. Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 300,000 options to buy
@ $1.66, valued at
$498k
|
|
| 06/09/2023 |
4
| Kaplin Adam (Chief Scientific Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 150,000 options to buy
@ $1.66, valued at
$249k
|
|
| 06/09/2023 |
4
| Uzonwanne Jude (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 150,000 options to buy
@ $1.66, valued at
$249k
|
|
| 06/09/2023 |
4
| Schreiber Christopher C (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 150,000 options to buy
@ $1.66, valued at
$249k
|
|
| 06/09/2023 |
4
| EAGLE CRAIG (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 475,000 options to buy
@ $1.66, valued at
$788.5k
|
|
| 06/09/2023 |
4
| Silverman Joshua (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 200,000 options to buy
@ $1.66, valued at
$332k
|
|
| 06/09/2023 |
4
| White Billy Joe (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 150,000 options to buy
@ $1.66, valued at
$249k
|
|
| 06/09/2023 |
4
| Rivard Paul (Chief Legal Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 150,000 options to buy
@ $1.66, valued at
$249k
|
|
| 06/09/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/05/2023 |
4
| Chapman Christopher C JR (President, Chief Med. Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.|
Txns:
| Granted 750,000 options to buy
@ $1.55, valued at
$1.2M
|
|
| 04/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/22/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/22/2023 |
8-K
| Other Events Interactive Data |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/08/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/02/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/28/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|